Ross Sutherland

Retatrutide reduces body fat by 24% in 24 weeks while PRESERVING muscle mass. Not Ozempic. Not Mounjaro. This is a triple agonist: GLP-1 + GIP + glucagon receptor. Clinical trial, 48 weeks: • Body weight: -24.2% average • Fat loss: significant • Lean muscle mass: PRESERVED • Metabolic markers: dramatically improved Here’s why this is different: Ozempic/Mounjaro = dual agonists (GLP-1 + GIP) → Suppress appetite → You eat less → Lose weight but also muscle Retatrutide = adds glucagon receptor → Suppresses appetite AND → Activates fat burning directly → Body uses fat for fuel instead of breaking down muscle Blood work improvements tracked in trials: • Fasting glucose: normalized • Triglycerides: -40% • Inflammatory markers: reduced • Insulin sensitivity: significantly improved The metabolic difference: Dual agonists: Force you to eat less (suffer through hunger, lose muscle) Retatrutide: Reprograms metabolism to PREFER burning fat (appetite controlled, muscle preserved) DEXA scans in the study confirmed: Fat mass dropped dramatically. Lean mass stayed intact. This isn’t starvation weight loss. This is your body finally burning stored fat the way it’s supposed to. Typical dosing protocol: Start 2mg weekly, titrate up to 8-12mg based on tolerance. Compare the outcomes: • Ozempic: 15% weight loss, muscle loss common, nausea frequent • Retatrutide: 24% fat loss, muscle preserved, better tolerance profile One forces calorie restriction. The other fixes fat metabolism.

🤗